Novartis to buy neuroscience firm Cadent Therapeutics for up to $770m
Based in Cambridge of Massachusetts, Cadent Therapeutics is involved in the development of therapies to treat cognitive, mood, and movement disorders. Cadent will secure a $210m upfront payment,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.